News | October 31, 2023
Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
Subscribe To Our Newsletter & Stay Updated
